Compare Ascendis Pharma A/S (ASND) vs iShares MSCI Taiwan ETF (EWT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs iShares MSCI Taiwan ETF — how do they compare? Ascendis Pharma A/S trades at $263.72 (market cap $17.74B), while iShares MSCI Taiwan ETF trades at $102.89. Which is the better fit depends on your goals.
| ASND | EWT | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $277.18 | $111.53 |
52-Week Low | $163.32 | $57.81 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
EWT trades at $106.17, up 1.07% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF has more than doubled in the past year, driven by Taiwan's semiconductor sector dominance and AI infrastructure demand. Recent news highlights strong performance comparisons against the S&P 500 and geopolitical tensions with China.
Outlook remains positive due to AI-driven semiconductor demand, but risks include geopolitical tensions and potential dollar reversals. The ETF's concentration in Taiwan tech offers growth but requires monitoring of regional stability and currency fluctuations for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →
